Abstract 125P
Background
The Network meta-analysis (NMA) of survival data is often based on the reported hazard ratios and relies on the proportional hazard (PH) assumption. To address the violation of the PH assumption, a non-proportional hazard (NPH) NMA was conducted using pseudo-patient-level data to assess the comparative efficacy of PD-1 inhibitors and chemotherapy in second-line treatment for advanced esophageal squamous cell carcinoma.
Methods
Embase and MEDLINE databases were searched for randomized controlled trials (RCTs) assessing PD-1 inhibitors for the treatment of ESCC. The Kaplan-Meier curves of overall survival (OS) from selected studies were digitized to generate pseudo-patient-level data using the Guyot algorithm. PH assumption testing was performed for all included studies and was found to be violated in multiple studies. A series of parametric models were fitted to the pseudo-patient-level data generated from the available KM curves using the method suggested by Ouwens et. al. The parametric NMA was performed using the “survivalnma” package in R. The Gelman-Rubin diagnostic, a measure of convergence for a list of Markov chain Monte Carlo (MCMC) sequences, was used to evaluate the convergence of the model.
Results
Five parametric distribution-based models (Exponential, Weibull, Gompertz, Log-normal, and Log-logistic) were considered for the NPH NMA. Based on the goodness of fit statistic, the best-fitted model was log-normal having a deviance information criterion (DIC) is 1445.7. The 3-year predicted survival of camrelizumab, nivolumab, sintilimab, pembrolizumab, tislelizumab and chemotherapy was 12%, 12%, 16%, 11%, 16% and 4%, respectively. The results should be interpreted with caution as the included trials were heterogeneous in terms of sample size, trial setting, and geography.
Conclusions
Parametric NMA is suitable for analyzing the comparative efficacy of multiple treatments in the presence of NPH as these methods leverage the use of distributional estimates (shape and scale) to conventional parametric survival models, fitted to patient-level data from the studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Heorlytics PVT. Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
Presenter: Qingbao Cheng
Session: Poster viewing 02
89P - Radiotherapy followed by camrelizumab for unresectable biliary tract cancer: A phase II clinical trial
Presenter: Zhenwei Peng
Session: Poster viewing 02
90P - Feasibility of using tumor-informed circulating tumor DNA (ctDNA)-based testing for patients with anal squamous cell carcinoma
Presenter: Georges Azzi
Session: Poster viewing 02
92P - Safety of liver resection following atezolizumab plus bevacizumab treatment in hepatocellular carcinoma (HCC) patients with macrovascular invasion: A pre-specified analysis of the TALENTop study
Presenter: Huichuan Sun
Session: Poster viewing 02
93P - Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Takuji Okusaka
Session: Poster viewing 02
94P - The treatment burden of neoadjuvant carboplatin/paclitaxel versus 5-fluorouracil/cisplatin in combination with radiotherapy for patients with esophageal cancer
Presenter: Chun-Ling Chi
Session: Poster viewing 02
95P - Additional survival follow-up of TACTICS-L: Transcatheter arterial chemoembolization therapy (TACE) in combination strategy with lenvatinib in (LEN) patients with unresectable hepatocellular carcinoma in Japan
Presenter: Yoshitaka Inaba
Session: Poster viewing 02
96P - Preoperative chemotherapy flot vs dox in patients of locally advanced gastric adenocarcinoma
Presenter: POORNIMA DEVI UTHAYAKUMAR
Session: Poster viewing 02
97P - BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma
Presenter: Nai-Jung Chiang
Session: Poster viewing 02